Leuprolide

Approved source records

1. The Effect of Leuprolide Acetate 11.25 mg 3-Month Formulation in Children with Central Precocious Puberty: A Systematic Review and Meta-analysis.

   Linqi Han, Chunjuan Zhai, La Da, Yan Sun · Advances in therapy · 2025

   DOI: 10.1007/s12325-025-03222-7PMID: 40498278

2. Effectiveness of leuprolide acetate administered monthly compared to three-monthly in the treatment of central precocious puberty: evaluation at the end of treatment.

   Thanaporn Thaneetrakool, Suphab Aroonparkmongkol, Nattakarn Numsriskulrat, Vichit Supornsilchai, Suttipong Wacharasindhu, Khomsak Srilanchakon · Frontiers in endocrinology · 2024

   DOI: 10.3389/fendo.2024.1390674PMID: 38737553

3. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.

   Ronald Tutrone, Fred Saad, Daniel J George, Bertrand Tombal, James L Bailen, Michael S Cookson, Daniel R Saltzstein, Sarah Hanson, Bruce Brown, Sophia Lu, Mark Fallick, Neal D Shore · European urology oncology · 2024

   DOI: 10.1016/j.euo.2023.11.024PMID: 38143206

4. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.

   Stephen J Freedland, Murilo de Almeida Luz, Ugo De Giorgi, Martin Gleave, Geoffrey T Gotto, Christopher M Pieczonka, Gabriel P Haas, Choung-Soo Kim, Miguel Ramirez-Backhaus, Antti Rannikko, Jamal Tarazi, Swetha Sridharan · The New England journal of medicine · 2023

   DOI: 10.1056/nejmoa2303974PMID: 37851874

5. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.

   Renato D Lopes, Celestia S Higano, Susan F Slovin, Adam J Nelson, Robert Bigelow, Per S Sørensen, Chiara Melloni, Shaun G Goodman, Christopher P Evans, Jan Nilsson, Deepak L Bhatt, Noel W Clarke · Circulation · 2021

   DOI: 10.1161/circulationaha.121.056810PMID: 34459214

6. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.

   Neal D Shore, Fred Saad, Michael S Cookson, Daniel J George, Daniel R Saltzstein, Ronald Tutrone, Hideyuki Akaza, Alberto Bossi, David F van Veenhuyzen, Bryan Selby, Xiaolin Fan, Vicky Kang · The New England journal of medicine · 2020

   DOI: 10.1056/nejmoa2004325PMID: 32469183

7. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.

   Neal D Shore, Sílvia Guerrero, Rosa Ma Sanahuja, Gemma Gambús, Antonio Parente · Clinical therapeutics · 2019

   DOI: 10.1016/j.clinthera.2019.01.004PMID: 30929678

8. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.

   Eva M Bolton, Thomas Lynch · BJU international · 2018

   DOI: 10.1111/bju.14168PMID: 29438592

9. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.

   E David Crawford, B Tombal, T Keane, F Boccardo, K Miller, N Shore, J W Moul, J-E Damber, L Collette, B-E Persson · Scandinavian journal of urology · 2018

   DOI: 10.1080/21681805.2018.1522372PMID: 30624128

10. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation.

    Peter A Lee, Margaret Luce, Peter Bacher · Journal of pediatric endocrinology & metabolism : JPEM · 2016

    DOI: 10.1515/jpem-2016-0026PMID: 27740929

11. Gonadotropin and Estradiol Levels after Leuprolide Stimulation Tests in Brazilian Girls with Precocious Puberty.

    Flavia R R Junqueira, Lucia A S Lara, Wellington P Martins, Rui A Ferriani, Ana Carolina J S Rosa-E-Silva, Marcos Felipe S de Sá, Rosana M Reis · Journal of pediatric and adolescent gynecology · 2015

    DOI: 10.1016/j.jpag.2014.09.006PMID: 26094907

12. Ulipristal acetate versus leuprolide acetate for uterine fibroids.

    Jacques Donnez, Janusz Tomaszewski, Francisco Vázquez, Philippe Bouchard, Boguslav Lemieszczuk, Francesco Baró, Kazem Nouri, Luigi Selvaggi, Krzysztof Sodowski, Elke Bestel, Paul Terrill, Ian Osterloh · The New England journal of medicine · 2012

    DOI: 10.1056/nejmoa1103180PMID: 22296076

13. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients.

    Ulf W Tunn · BMC urology · 2011

    DOI: 10.1186/1471-2490-11-15PMID: 21801354

14. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain.

    David S Guzick, Li-Shan Huang, Betsy A Broadman, Maureen Nealon, Mark D Hornstein · Fertility and sterility · 2011

    DOI: 10.1016/j.fertnstert.2011.01.027PMID: 21300339

15. Utility of single luteinizing hormone determination 3 h after depot leuprolide in monitoring therapy of gonadotropin-dependent precocious puberty.

    Shrikrishna V Acharya, Raju A Gopal, Joe George, Tushar R Bandgar, Padma S Menon, Nalini S Shah · Pituitary · 2009

    DOI: 10.1007/s11102-009-0184-0PMID: 19396631

16. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

    Laurence Klotz, Laurent Boccon-Gibod, Neal D Shore, Cal Andreou, Bo-Eric Persson, Per Cantor, Jens-Kristian Jensen, Tine Kold Olesen, Fritz H Schröder · BJU international · 2008

    DOI: 10.1111/j.1464-410x.2008.08183.xPMID: 19035858

17. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.

    C F Heyns, M-P Simonin, P Grosgurin, R Schall, H C Porchet, South African Triptorelin Study Group · BJU international · 2003

    DOI: 10.1046/j.1464-410x.2003.04308.xPMID: 12887472

18. Comparison of leuprolide acetate and triptorelin in assisted reproductive technology cycles: a prospective, randomized study.

    Raoul Orvieto, Ram Kerner, Haim Krissi, Jacob Ashkenazi, Zion Ben Rafael, Itai Bar-Hava · Fertility and sterility · 2002

    DOI: 10.1016/s0015-0282(02)04262-0PMID: 12477523

19. Randomized double-blind study evaluating the efficacy on uterine fibroids shrinkage and on intra-operative blood loss of different length of leuprolide acetate depot treatment before myomectomy.

    V M Jasonni, R D'Anna, A Mancuso, C Caruso, F Corrado, I Leonardi · Acta obstetricia et gynecologica Scandinavica · 2001

    DOI: 10.1034/j.1600-0412.2001.801014.xPMID: 11580742

20. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.

    M D Hornstein, E S Surrey, G W Weisberg, L A Casino · Obstetrics and gynecology · 1998

    DOI: 10.1016/s0029-7844(97)00620-0PMID: 9464714

21. Absence of a dose-response effect of leuprolide acetate on leiomyomata uteri size.

    R J Kiltz, J Rutgers, J Phillips, M L Murugesapillai, O A Kletzky · Fertility and sterility · 1994

    PMID: 8194611

22. Gonadotropin-releasing hormone agonist use before hysterectomy.

    T G Stovall, R L Summit, S A Washburn, F W Ling · American journal of obstetrics and gynecology · 1994

    PMID: 8203435

23. Role of leuprolide acetate depot in hysteroscopic surgery: a controlled study.

    A Perino, N Chianchiano, M Petronio, E Cittadini · Fertility and sterility · 1993

    DOI: 10.1016/s0015-0282(16)55790-2PMID: 8458448

24. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

    E D Crawford, M A Eisenberger, D G McLeod, J T Spaulding, R Benson, F A Dorr, B A Blumenstein, M A Davis, P J Goodman · The New England journal of medicine · 1989

    DOI: 10.1056/nejm198908173210702PMID: 2503724

25. Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration.

    L T Sennello, R A Finley, S Y Chu, C Jagst, D Max, D E Rollins, K G Tolman · Journal of pharmaceutical sciences · 1986

    DOI: 10.1002/jps.2600750211PMID: 3083092